Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2323 | Mefloquine Wiki | 1.00 |
| drug2324 | Mefloquine + azithromycin + / - tocilizumab Wiki | 1.00 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
Navigate: Correlations HPO
There is one clinical trial.
Study of the effectiveness and safety of the drug Mefloquine, tablets 250 mg, produced by FSUE "SPC" Farmzaschita " FMBA of Russia (Russia), in comparison with the drug Hydroxychloroquine, tablets 200 mg, for the treatment of patients with coronavirus infection, in the "off-label" mode, to make a decision on the possibility of expanding the indications for use.
Description: The number of patients with development of respiratory failure requiring transfer to the ICU.
Measure: 1st primary endpoint for group 1 Time: up to 10 daysDescription: The period of clinical recovery.
Measure: 2nd primary endpoint for group 1 Time: up to 10 daysDescription: The period of clinical recovery.
Measure: 1st primary endpoint for group 2 Time: up to 10 daysDescription: Frequency of fatal outcomes associated with coronavirus infection disease (COVID19)
Measure: 2nd primary endpoint for group 2 Time: through study completion, an average of 3 monthsDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 1 Time: on days 5 and 10Description: Frequency of clinical cure on day 10 from the start of therapy
Measure: 2nd secondary endpoint for group 1 Time: on day 10Description: The retention time of the reaction temperature from the start of the treatment.
Measure: 3d secondary endpoint for group 1 Time: up to 10 daysDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 1 Time: up to 10 daysDescription: Respiratory index.
Measure: 5th secondary endpoint for group 1 Time: up to 10 daysDescription: Frequency appearance unwanted phenomena and serious unwanted phenomena
Measure: 6th secondary endpoint for group 1 Time: up to 10 daysDescription: A change in viral load by conducting PCR assay through different timeframes
Measure: 1st secondary endpoint for group 2 Time: on days 5 and 10Description: Respiratory index.
Measure: 2nd secondary endpoint for group 2 Time: up to 10 daysDescription: The retention time of the reaction temperature from the start of treatment.
Measure: 3d secondary endpoint for group 2 Time: up to 10 daysDescription: Concentration of C-reactive protein in blood plasma.
Measure: 4th secondary endpoint for group 2 Time: up to 10 daysDescription: Number of patients required transition to alternative therapy schedule
Measure: 5th secondary endpoint for group 2 Time: up to 10 daysDescription: Frequency of adverse events and serious adverse events
Measure: 6th secondary endpoint for group 2 Time: up to 10 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports